PLACE A FREE AD
News categories  -  Endoscopy  -  Endoscopy

NEW CLINICAL DATA SHOWING THE EFFICACY OF THE FUSE FULL SPECTRUM ENDOSCOPY SYSTEM WAS PRESENTED AT DDW 2016

The medical equipment manufacturer EndoChoice Holdings recently participated in the DDW conference dedicated to diseases of the digestive tract, which was held in San Diego, California. During the event, EndoChoice not only showed off their new products, but also presented the results of clinical studies performed using those same products. At the conference, visitors could sit it on presentations, try out new devices and also buy endoscopic equipment.

According to CEO Mark Gilreath, the main focus of his company is to manufacture and improve the Fuse Full Spectrum Endoscopy system. It's important to note that this device has three fiber-optic cameras instead of the usual one, which greatly increases the visual accessibility of the intestine. Recent studies have shown that this system has a positive effect on clinical outcomes in patients.

For example, in a recent study conducted in New York, that included 25 doctors and 4,163 patients, each of whom underwent endoscopy using a standard colonoscope and using the new Fuse system. The adenoma detection rate (ADR) represents the number of identified, histologically confirmed adenomas, divided by the total number of performed endoscopies. The results of the study support the use of the new colonoscopy system, whose ADR was 29%. Standard colonoscopy, on the other hand, had an ADR of 23.5%, clearly a significant difference.

The main author of the study Blair Lewis stated that the above-mentioned data was collected during routine endoscopy procedures in one of the many clinical centers in New York. This shows the high specificity of the device and that fact that special skills aren't required to work with it.

Having analyzed the studies performed using the new colonoscopy system, it can be said with confidence that the Fuse Full Spectrum Endoscopy system significantly increases the chances of detecting pre-cancerous colon diseases. This is a great incentive to buy endoscopic equipment for each clinical center dedicated to the treatment of diseases of the digestive tract.

By Yuri Lovitsky, BiMedis staff writer

13.07.2016

WRITE A COMMENT